Study Reveals How Louse-Borne Relapsing Fever Bacterium Evades Immune System
Researchers have identified mechanisms by which Borrelia recurrentis, the spirochete bacterium that causes louse-borne relapsing fever, evades the human immune system. The disease, transmitted by body lice and characterized by recurring fever episodes, has been documented since ancient times and remains fatal in up to 20% of untreated cases, particularly in regions with limited medical access. Understanding these immune evasion mechanisms could inform better treatment and prevention strategies for this neglected tropical disease.
Louse-borne relapsing fever is caused by the spirochete bacterium Borrelia recurrentis, transmitted through body lice rather than head lice. The disease presents with initial high fever lasting several days, followed by fever-free intervals and typically multiple recurrent fever episodes. First documented by Hippocrates in ancient Greece, the infection remains a significant health concern in regions with limited healthcare infrastructure. While antibiotics can treat the disease, untreated infection carries a fatality rate of up to 20%. Recent research has focused on elucidating how the bacterium evades immune system defenses, which could lead to improved therapeutic approaches.
What's missing
The article does not specify which immune evasion mechanisms were identified in the research or provide details about the study's methodology, findings, or the researchers involved.
What different sources said
- Medical XpressCenter
How a louse-borne pathogen evades the immune system
Related
Sydney Psychiatrist Retains Medical License After Sexual Assault Conviction
Gopi Ilawala, a Sydney psychiatrist convicted of sexually assaulting an intoxicated colleague in 2022, has been allowed to continue practicing medicine despite the state health regulator seeking to have his registration cancelled. The New South Wales Civil and Administrative Tribunal reprimanded him and imposed conditions rather than striking him off, citing his remorse, lack of prior convictions, and support from two senior psychiatrists. The decision raises questions about professional accountability and public protection in medical regulation.
Australia's TGA to crack down on illegal peptides; government allocates $100m for arthritis research
Australia's Therapeutic Goods Administration has announced a crackdown on illegal peptides due to a surge in imports and online advertising, designating them a priority focus area. The federal government has simultaneously committed $100 million to medical research into arthritis prevention, diagnosis, and treatment. These developments reflect growing regulatory concerns about unregulated drugs and increased investment in chronic disease research.
GLP-1 Drugs Like Ozempic May Help ADHD Symptoms, According to Patient Reports and Clinical Observations
Social media users and some patients are reporting that GLP-1 receptor agonist drugs like Ozempic appear to improve ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. GLP-1s were originally developed to treat Type 2 diabetes but are being studied for various other conditions. While anecdotal reports are growing, no formal clinical trials are currently testing these drugs specifically for ADHD, and the mechanism behind any potential benefit remains unclear.